Patent · US Active

Recombinant binding proteins targeting HER2 and serum albumin, and their uses

US10717772B2 · kind B2 · utility

4Cited by

15References

20Claims

0Family size

Assignee

Molecular Partners AG · CH

Inventors

Clara METZ · Schlieren, CH
Ulrike Fiedler · Bodenwerder, DE
Ignacio Dolado · Rheinfelden, CH
Heike Strobel · Basel, CH

Key dates

Filing date	Sep 20, 2017
Grant date	Jul 21, 2020
Priority date	—
Expiry date	Sep 20, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

New recombinant binding proteins, comprising designed ankyrin repeat domain(s) with binding specificity for HER2, and comprising designed ankyrin repeat domain(s) with binding specificity for serum albumin, are disclosed, as well as nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.